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Endometrialcanceristhemostcommonmalignancyofthefemalegenitaltract.Surgicaltreatmentincludeshysterectomy,bilateral
salpingo-oophorectomy, and an appropriatestaging procedure. Relapse of endometrial cancer may occur in patients with high risk
factors, such as old age, grade 3 cancer, deep myometrial invasion, and papillary serous and clear cell types. In recent years, several
randomized trials reported the results of adjuvant therapy for patients with high risk factors. Nonetheless, some controversies still
exist. This paper presents and discusses the results of important randomized trials of adjuvant therapy for endometrial cancer with
risk factors.
1.Introduction
Endometrial cancer (EC) is the most common malignancy
of the female genital tract in the Western world with an
annual incidence of 15–18/100,000 women [1]. Around
80% of EC patients is diagnosed in the early period of
the disease and has a good prognosis. Surgical treatment,
including hysterectomy, bilateral salpingo-oophorectomy,
and an appropriate surgical staging workup. should be
performedinallpatientswithEC.Forbettercommunication
of the text below, the following descriptions of previous
randomized trials are based on the International Federation
of Gynecology and Obstetrics (FIGO) 1988 classiﬁcation
systeminsteadoftheFIGO2009stagingsystem.Nonetheless,
it is noteworthy to understand that stage IA and stage IB of
theFIGO1988stagingsystemaremergedasstageIAofFIGO
2009 staging system; stage IIA is merged with stage I; positive
cytology has to be reported separately without changing the
stage;stageIIICissubdividedintostageIIIC1(nopara-aortic
lymph node metastasis) and stage IIIC2 (with para-aortic
lymph node metastasis) [2].
Based on the National Comprehensive Cancer Network
(NCCN) guidelines, observation is recommended for stage
I A ,g r a d e1( G 1 )o rg r a d e2( G 2 )a n ds t a g eI B ,G 1p a t i e n t s
with no adverse prognostic factors [3]. R¨ oper et al. reported
the major prognostic factors for early-stage EC to include
older age, histologic type (i.e., serous or clear cell type),
high histologic grade, deep myometrial invasion, lympho-
vascular space invasion (LVSI), large tumor size (>2cm),
and involvement of the lower uterine segment or cervix [4].
The indication of adjuvant chemotherapy or radiotherapy is
based on risk factors of recurrence. Nowadays, controversies
still exist about postoperative adjuvant chemotherapy or
radiotherapyforearlyECwithadverseprognosticfactorsand
for advanced EC.
It is suggested that all women with FIGO stage IB, IC,
IIA (occult: cervical extension without clinical evidence of
cervical enlargement), and IIB (occult) and no evidence of
lymph node involvement should be considered as mem-
bers of the intermediate risk group [5]. The Gynecologic
Oncology Group (GOG) 99 trial [6] further deﬁned high-
intermediate and low-intermediate risk groups from the
GOG 33 [5]. High-intermediate risk is deﬁned as: (1) at least
70 years of age with only one of the other risk factor (i.e.,
moderate to poorly diﬀerentiated tumor grade, presence of
LVSI, and deep (>2/3) myometrial invasion), (2) at least 502 ISRN Obstetrics and Gynecology
years of age with any two of the other risk factors, or (3)
any age with all three of the other risk factors. All other
patients in the intermediate risk group are deﬁned as being
in the low-intermediate risk group [6]. High risk is deﬁned
as having clear or serous cell type, gross involvement of the
cervix (gross stage II), stage III, or stage IV. It must be noted
that most trials did not enroll the pure high-intermediate
risk or high risk patients for randomization. Nonetheless, we
attempt to discuss adjuvant therapy from the perspectives of
diﬀerent risk factor subgroups by analyzing the results of the
randomized trials.
2. AdjuvantTherapy for Low and
Low-IntermediateRiskGroupsofECPatients
The risk of locoregional recurrence for EC patients with
G1and G2 endometrioid cell type and superﬁcial (<50%)
myometrial invasion is about 5% or less [7, 8]. There is no
evidence of beneﬁt to support the use of adjuvant therapy
for low and low-intermediate risk groups; therefore, these
patients can be safely treated by surgery only [8], despite
vaginal brachytherapy (VBT) use for adjuvant treatment for
low-intermediate risk patients [4]. Besides, it was concluded
that postoperative radiotherapy is not indicated in stage I
patients <60 years of age and patients with G2 tumors with
superﬁcial invasion from the result of the Post-Operative
Radiation Therapy in Endometrial Carcinoma (PORTEC)-1
trial (external beam radiotherapy 46 Gy versus observation)
[9].
3. AdjuvantTherapy for the High-Intermediate
Risk Groupof ECPatients
According to NCCN guidelines, external beam radiotherapy
(EBRT), VBT, or both, or observation can be performed
for high-intermediate risk patients [2]. In the PORTEC-1
trial, patients with stage I (G1 with outer-half myometrial
invasion, G2 with any invasion, or grade 3 with superﬁcial
myometrial invasion) were randomized to pelvic EBRT
(46Gy) or no further treatment after surgery. Postoperative
EBRT for stage I patients reduced locoregional recurrence
but had no impact on overall survival (OS) [9, 10]. Addi-
tionally, EBRT increased treatment-related morbidity [9]. In
the GOG 99 trial, adjuvant EBRT (50.4Gy) for stage IB, IC,
and II (occult) patients had a substantial positive impact
on 2-year cumulative recurrence (12% in the observation
group and 3% in the EBRT group, P = 0.007), especially
in the high-intermediate risk group. The estimated 4-year
OS did not diﬀer between the observation and the EBRT
groups (86% versus 92%, P = 0.56, resp.) [6]. In the
ASTEC/EN.5 trial, patients with high-intermediate and high
risk (including stage IA and IB grade 3, IC of all grades, and
serous or clear cell histology) were randomized to receive
postoperative adjuvant EBRT (40–46Gy) or observation.
The results showed that EBRT could not be recommended
as part of routine treatment for women with intermediate-
risk or high-risk early-stage endometrial cancer with the aim
of improving survival [11]. The absolute beneﬁt of EBRT
in preventing isolated local recurrence is small and is not
without toxicity [11].
In the PORTEC-2 trial, patients with high-intermediate
risk (age >60 years and stage IC G1 or G2 disease, stage IB
grade 3 disease, or any age and stage IIA disease) were ran-
domized to receive pelvic EBRT (46Gy) or VBT (21Gy high-
dose rate or 30Gy low-dose rate). Five-year locoregional
recurrence rate (EBRT versus VBT = 2.1% versus 5.1%,
P = 0.17), OS (79.6% versus 84.8%, P = 0.57) or disease-
free survival (DFS, 78.1% versus 82.7%, P = 0.74) did not
diﬀer between these two groups. It was concluded that VBT
is eﬀective in ensuring vaginal control and a better quality
of life, with fewer gastrointestinal toxic eﬀects than with
EBRT. Accordingly, VBT should be the adjuvant treatment of
choice for patients with high-intermediate risk of recurrence
[12, 13]. Nonetheless, is there any role for EBRT? Kong et
al. reported that in stage I patients with multiple high risk
factors, including stage IC and grade 3 (G3), the risk ratio
of EC-related death is 0.65 (95% conﬁdence interval 0.38 to
1.14, P = 0.13) after adjuvant EBRT [14].
In addition, is there any role for adjuvant chemotherapy
(CT) for high intermediate risk patients? In a Finnish
trial, patients with stages IA-IB G3 (n = 28) or IC–IIIA
grades 1–3 (n = 128) were randomized to receive pelvic
EBRT (56Gy) or chemoradiotherapy (EBRT combined with
three courses of cisplatin-epirubicin-cyclophosphamide).
The addition of CT failed to improve OS or the recurrence
rate, but appeared to increase bowel complications [1]. In
the Japanese Gynecologic Oncology Group (JGOG) 2003
randomized trial, stage IC–IIIC patients with deep (≥50%)
myometrial invasion and <75 years of age received adjuvant
pelvic RT (greater than 90% of patients received 45–50Gy
EBRT only) or cyclophosphamide-doxorubicin-cisplatin for
3o rm o r ec o u r s e s[ 15]. A subgroup analysis revealed that the
5-year progression-free survival (PFS) rates in the RT and
CT groups were 94.5% and 87.6%, resp. (P = 0.11); the 5-
yearOSrateswere95.1%and90.8%,respectively(P = 0.28).
However, among these 120 patients with stage IC, >70 years
of age, or G3 endometrioid cell type or stage II or IIIA
(positive cytology) with outer-half myometrial invasion, the
CT group had signiﬁcantly higher PFS rate (83.8% versus
66.2%, P = 0.02) and OS rate (89.7% versus 73.6%, P =
0.006) compared to that of the RT group [15]. Nonetheless,
the above results were derived from post hoc analysis. Thus,
the ideal adjuvant therapy for high-intermediate risk EC
patients remain undetermined. An ongoing GOG 249 trial
enrolled high risk stage I or II patients. These patients are
randomized to receive pelvic RT (conventional or intensity-
modulated EBRT with or without VBT) or VBT followed by
3 courses of carboplatin-paclitaxel [16].
4. AdjuvantTherapy for the High Risk
Group of EC Patients
In an Italian trial, patients at high risk of recurrence (i.e.,
stage IC and G3, stage II and G3 with outer-half myometrial
invasion, and stage III; two thirds of patients were stage
III) were randomized to receive adjuvant CT (ﬁve coursesISRN Obstetrics and Gynecology 3
of cisplatin-doxorubicin-cyclophosphamide) or EBRT (45–
50Gy). Survival did not diﬀer between the two groups
[17]. On the contrary, in the GOG 122 trial, patients with
stage III or IV and <2cm of postoperative residual tumor
were randomized to receive doxorubicin-cisplatin or whole-
abdominal irradiation (30Gy, with an additional 15-Gy
pelvic±para-aorticboost).PFSandOSwerebetterintheCT
group compared that of the RT group [18]. Thus, adjuvant
CT seemed not to be inferior to RT in the treatment of high
risk patients.
However,theissuesofwhichCTregimenisthetreatment
of choice for patients with high risk and advanced EC
remain undetermined. In the European Organization for
Research and Treatment of Cancer (EORTC) 55872 trial,
patients with advanced or recurrent EC were randomized
to receive doxorubicin or cisplatin-doxorubicin treatment.
The combined cisplatin-doxorubicin group had a higher
response rate (43% versus 17%, P<0.001) but no diﬀerence
in OS (9 months versus 7 months, P = 0.065) compared
with the doxorubicin group [19]. Sovak et al. reported that
the carboplatin-paclitaxel regimen is a well-tolerated, active
regimen for the treatment of resected stage III or IV high risk
patients with a 3-year OS rate of 56%, the median time to
progression of 13 months, and a median OS of 47 months
[20]. In the GOG 177 trial, patients with stage III or IV,
or recurrent EC were randomized to receive doxorubicin-
cisplatin or doxorubicin-cisplatin-paclitaxel (with ﬁlgrastim
support). The addition of paclitaxel to doxorubicin-cisplatin
improved objective response (57% versus 34%, P<0.01),
PFS (median: 8.3 versus 5.3 months, P<0.01), and OS
(median: 15.3 versus 12.3 months, P = 0.037). However, it
resultedinahigherrateofperipheralneuropathy[21].There
isanongoingGOG209trialofpatientswithstageIIIorIV,or
recurrent EC randomized to receive doxorubicin-cisplatin-
paclitaxel (with ﬁlgrastim support) or carboplatin-paclitaxel
for seven courses. The results of this ongoing trial may give
us the answer of the appropriate chemotherapy regimen for
the treatment of advanced EC [22].
Another question is whether the combined chemora-
diotherapy is a better treatment choice for high risk EC
patients. Klopp et al. reported stage IIIC patients treated
without RT (EBRT ± VBT) had a high rate of locoregional
recurrence. Additionally, relapse after RT for IIIC patients
mainly occurred in G3 patients who may be likely to
beneﬁt from combined chemoradiotherapy [23]. In the
EORTC 55991 trial (abstract only), patients with stages
I, II, IIIA (positive cytology only), and IIIC (excluding
para-aortic metastases) and clear, serous, and anaplastic
cell types were enrolled. Most patients had two or more
risk factors including G3, deep myometrial invasion, or
DNA nondiploidy. Enrolled patients were randomized to
RT (EBRT ± VBT) or combined chemoradiotherapy. The
chemotherapy regimen before August 2004 was cisplatin-
doxorubicin or -epirubicin; thereafter, it was changed to
cisplatin-doxorubicin or -epirubicin, paclitaxel-epirubicin-
carboplatin, or paclitaxel- carboplatin. The hazard ratio for
PFS was 0.58 in favor of the combined chemoradiotherapy
group (P = 0.046), and a 7% diﬀerence in estimated 5-year
PFS was found [24]. There is an ongoing PORTEC-3 trial
in which high-intermediate and high risk patients (stage IB
with LVSI and G3, stage II and G3, stage IIIA or IIIC, and
stage IB-III and serous or clear cell type) were randomized
to pelvic EBRT (48.6Gy) alone or concurrent chemoradio-
therapy (EBRT and two courses of cisplatin) followed by
adjuvant CT (carboplatin and paclitaxel for four courses).
The results could tell us if the addition of concurrent and
adjuvant CT to postoperative RT will increase 5-year OS
and failure-free survival or not [25]. Additionally, there is
an ongoing GOG 258 trial in which patients (stages I and II
with serous or clear cell type and positive cytology, stage III-
IVA) were randomized to receive carboplatin and paclitaxel
for six courses or concurrent chemoradiotherapy (EBRT ±
VBT and two courses of cisplatin) followed by four courses
of carboplatin and paclitaxel [26].
In conclusion, the adjuvant treatment of choice for high-
intermediate and high risk EC patients remains undeter-
mined. Adjuvant therapy should be considered according
to individual risk factors. Ongoing trials could resolve the
controversies of adjuvant therapy in EC once they are
completed.
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